ValuEngine upgraded shares of Zealand Pharma (NASDAQ:ZEAL) from a sell rating to a hold rating in a report published on Wednesday.
Separately, Zacks Investment Research lowered shares of Zealand Pharma from a hold rating to a sell rating in a research report on Thursday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Zealand Pharma currently has a consensus rating of Buy and an average target price of $24.75.
ZEAL opened at $15.22 on Wednesday. The stock has a market cap of $467.73 and a P/E ratio of -10.28. Zealand Pharma has a fifty-two week low of $12.45 and a fifty-two week high of $20.37.
Zealand Pharma (NASDAQ:ZEAL) last posted its quarterly earnings results on Wednesday, March 7th. The company reported ($0.58) earnings per share for the quarter. The company had revenue of $1.78 million for the quarter. Zealand Pharma had a negative net margin of 200.15% and a negative return on equity of 68.26%.
Institutional investors and hedge funds have recently bought and sold shares of the stock. OLD Mission Capital LLC bought a new position in Zealand Pharma during the fourth quarter valued at about $215,000. Fred Alger Management Inc. bought a new position in Zealand Pharma during the fourth quarter valued at about $544,000. Finally, AWM Investment Company Inc. grew its position in Zealand Pharma by 8.1% during the fourth quarter. AWM Investment Company Inc. now owns 302,901 shares of the company’s stock valued at $4,119,000 after buying an additional 22,700 shares during the period. Institutional investors own 9.07% of the company’s stock.
Zealand Pharma Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zealand Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma and related companies with MarketBeat.com's FREE daily email newsletter.